Please note: B-SMART concluded its activities in June 2022.

Innovative nanotechnological RNA delivery systems targeting the direct cause of Alzheimer‘s disease instead of its symptoms

Neurodegenerative diseases such as Alzheimer’s affect over 7 million people in Europe. Despite this fact, few treatments for this group of diseases are available so far. Nanomedical approaches can make a difference, providing new therapeutic options by helping drugs to enter the brain.

Therefore, the multinational research project B-SMART sets out to provide an RNA-based therapy perspective for neurodegenerative diseases targeting the direct cause of the disease instead of its symptoms in the midterm.

  • Learn how far B-SMART has come in their collaborative endeavour in this new Video Clip which highlights project’s pathway to success

  • Learn about our ideas and objectives: The animated B-SMART film

  • Learn more about B-SMART and what working in an international research project means to the young scientists in our project

News & Events

"Transferring RNA therapeutics to the brain crossing the blood-cerebrospinal fluid barrier is a unique research endeavor. Finding a novel gateway to transport RNA to the brain will enable the development of causal therapies not only for Alzheimer’s, but for other diseases as well."

Photo of Prof. Raymond Schiffelers
Prof. Raymond Schiffelers (UMCU), Coordinator of B-SMART
Neurodegenerative Diseases
Icon 1

Lack of causal therapies and effective drugs

Icon 2

RNA-based nanomedicines directly targeting the brain

Icon 3

Secure in-vivo transport through nanocarriers

Icon 4

Crossing the blood-cerebrospinal fluid barrier through ligands

Proof of Concept
Icon 5

Basis technology for treatment of other diseases